Chasov, V., Zmievskaya, E., Ganeeva, I., Gilyazova, E., Davletshin, D., Mirgayazova, R., Khadiullina, R., Valiullina, A., Rizvanov, A., & Bulatov, E. (2023). Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T. Preprints. https://doi.org/10.20944/preprints202309.1136.v1
Chicago/Turabian Style
Chasov, V., Albert Rizvanov and Emil Bulatov. 2023 "Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T" Preprints. https://doi.org/10.20944/preprints202309.1136.v1
Abstract
Systemic autoimmune diseases (SAIDs) such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and rheumatoid arthritis (RA) are fully related to the unregulated innate and adaptive immune systems involved in their pathogenesis. They have similar pathogenic characteristics including the interferon signature, loss of tolerance to self-nuclear antigens, and enhanced tissue damage like necrosis and fibrosis. Glucocorticoids and immunosuppressants, which have limited specificity and are prone to tolerance, are used as the first-line therapy. A plethora of novel immunotherapies have been developed including monoclonal and bispecific antibodies, and other biological agents to target cellular and soluble factors involved in disease pathogenesis such as B cells, co-stimulatory molecules, cytokines or their receptors, and signalling molecules. Many of these have shown encouraging results in clinical trials. CAR-T cell therapy is considered the most promising technique for curing autoimmune diseases, with recent successes in the treatment of SLE and SSc.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
*
